title: Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
abstract: BACKGROUND
  Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.
  
  
  METHODS
  We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative disorder in the CNS.
  
  
  CONCLUSIONS
  Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections.
authors.affiliation: Department of Hematology and vascular disorders, Skåne University Hospital, Lund, Sweden ; Lund University, Lund, Sweden.
authors.forename: Róbert
authors.initials: R
authors.lastname: Pálmason
authors.affiliation: Department of Oncology, Skåne University Hospital, Lund, Sweden ; Lund University, Lund, Sweden.
authors.forename: Ola
authors.initials: O
authors.lastname: Lindén
authors.affiliation: Department of Hematology and vascular disorders, Skåne University Hospital, Lund, Sweden ; Lund University, Lund, Sweden.
authors.forename: Johan
authors.initials: J
authors.lastname: Richter
keywords: EBV; Lymphoma; Lymphoproliferative disorder; Ruxolitinib; Side-effects